What problem does it solve?
Assessing whether two or more medications can be safely combined requires checking CYP450 and UGT metabolism, transporter effects, pharmacodynamic overlap, FDA labels, and literature evidence across many databases, which is slow and error-prone when done manually.
Core Features & Use Cases
- Mechanism-based DDI analysis: Identifies perpetrator-victim relationships across CYP450, UGT glucuronidation, transporter (P-gp, OATP), and pharmacodynamic pathways, with bidirectional A→B and B→A evaluation.
- Evidence-graded risk scoring: Produces a 0-100 risk score and severity classification (Contraindicated/Major/Moderate/Minor) backed by FDA labels, PubMed literature, and FAERS adverse event data.
- Offline pharmacology reference: Ships a dependency-free script covering CYP/UGT roles, narrow therapeutic index drugs, and a curated database of critical interactions such as valproate + lamotrigine.
- Use Case: A clinician asks whether simvastatin can be taken with ketoconazole; the Skill flags the combination as contraindicated via CYP3A4 inhibition, cites the FDA label, and recommends pravastatin or rosuvastatin as safer alternatives.
Quick Start
Ask the agent to analyze the drug interaction between warfarin and amoxicillin and generate a DDI risk report with management recommendations.